Price
$132.62
Increased by +0.45%
Dollar volume (20D)
47.35 M
ADR%
3.92
Shares float
22.81 M
Shares short
2.60 M [11.40%]
Shares outstanding
28.90 M
Market cap
3.82 B
Beta
0.66
Price/earnings
31.36
20D range
122.80 141.37
50D range
122.80 196.15
200D range
122.80 207.84

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.

The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.

Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 5, 25 1.20
Increased by +3.89 K%
1.03
Increased by +16.14%
Feb 24, 25 1.53
Increased by +410.00%
1.85
Decreased by -17.39%
Nov 4, 24 0.91
Increased by +231.88%
0.90
Increased by +1.11%
Aug 5, 24 0.53
Increased by +142.40%
0.58
Decreased by -8.62%
May 6, 24 0.03
Increased by +101.70%
0.15
Decreased by -80.00%
Feb 26, 24 0.30
Increased by +124.00%
-0.38
Increased by +178.95%
Nov 6, 23 -0.69
Increased by +41.03%
-0.29
Decreased by -137.93%
Aug 7, 23 -1.25
Decreased by -13.64%
-0.74
Decreased by -68.92%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 88.18 M
Increased by +94.88%
35.73 M
Increased by +3.73 K%
Increased by +40.52%
Increased by +1.87 K%
Dec 31, 24 91.14 M
Increased by +116.26%
45.48 M
Increased by +423.23%
Increased by +49.90%
Increased by +141.94%
Sep 30, 24 83.84 M
Increased by +879.91%
27.18 M
Decreased by -66.34%
Increased by +32.42%
Decreased by -96.56%
Jun 30, 24 70.28 M
Increased by +N/A%
15.57 M
Increased by +146.88%
Increased by +22.15%
Decreased by N/A%
Mar 31, 24 45.25 M
Increased by +N/A%
932.00 K
Increased by +102.06%
Increased by +2.06%
Decreased by N/A%
Dec 31, 23 42.14 M
Increased by +N/A%
8.69 M
Increased by +127.12%
Increased by +20.63%
Decreased by N/A%
Sep 30, 23 8.56 M
Increased by +N/A%
80.75 M
Increased by +370.51%
Increased by +943.75%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-33.21 M
Decreased by -18.15%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY